HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyer, M. M. Articles by Klein, H. H. Search for Related Content PubMed PubMed Citation Articles by Meyer, M. M. Articles by Klein, H. H. Social Bookmarking                What's this?

Troglitazone Treatment Increases Protein Kinase B Phosphorylation in Skeletal Muscle of Normoglycemic Subjects at Risk for the Development of Type 2 Diabetes

¹ Medizinische Klinik 1, Medizinische Universität zu Lübeck, Lübeck, Germany
² Diabetes Research Center, Odense University Hospital, Odense, Denmark

We investigated whether the effect of troglitazone on glucose disposal is associated with altered insulin signaling. Nondiabetic first-degree relatives of type 2 diabetic patients (age 30 ± 2 years, BMI 30 ± 1 kg/m²; n = 20) were randomized in a double-blind manner to 3 months of troglitazone (200 mg/day) or placebo treatment. Before and after treatment, 3-h euglycemic-hyperinsulinemic glucose clamps (40 mU · m^-2 · min^-1) were performed, and muscle biopsies were obtained immediately before and after the clamps. In the biopsies, insulin receptor kinase (IRK) activity, insulin receptor substrate (IRS)-1-associated phosphatidylinositol 3-kinase (PI3K) activity, Ser⁴⁷³ and Thr³⁰⁸ phosphorylation of protein kinase B (PKB), and protein expression of IRS-1, IRS-2, phosphoinositol-dependent kinase-1 (PDK-1), PKB, and GLUT-4 were determined. After troglitazone treatment, insulin-stimulated glucose disposal was increased compared with pretreatment and placebo (279 ± 37 vs. 211 ± 26 and 200 ± 25 mg · m^-2 · min^-1; both P < 0.05). IRK and PI3K activities were not altered by troglitazone, but PKB Ser⁴⁷³ phosphorylation was enhanced compared with pretreatment and placebo at the clamp insulin level (138 ± 36 vs. 77 ± 16 and 55 ± 13 internal standard units; both P < 0.05) and with pretreatment at the basal level (31 ± 9 vs. 14 ± 4 internal standard units; P < 0.05). PKB Thr³⁰⁸ phosphorylation also tended to be higher, but this was not statistically significant. Troglitazone did not alter insulin receptor number or IRS-1, IRS-2, PKB, PDK-1, or GLUT-4 protein expression. We conclude that increased PKB phosphorylation may contribute to the insulin-sensitizing effects of thiazolidinediones in human skeletal muscle.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				K. Hojlund, D. Glintborg, N. R. Andersen, J. B. Birk, J. T. Treebak, C. Frosig, H. Beck-Nielsen, and J. F.P. Wojtaszewski Impaired Insulin-Stimulated Phosphorylation of Akt and AS160 in Skeletal Muscle of Women With Polycystic Ovary Syndrome Is Reversed by Pioglitazone Treatment Diabetes, February 1, 2008; 57(2): 357 - 366. [Abstract] [Full Text] [PDF]

				Y. Ye, Y. Lin, S. Atar, M.-H. Huang, J. R. Perez-Polo, B. F. Uretsky, and Y. Birnbaum Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1158 - H1169. [Abstract] [Full Text] [PDF]

				C.-Y. Lin, T. Gurlo, L. Haataja, W. A. Hsueh, and P. C. Butler Activation of Peroxisome Proliferator-Activated Receptor-{gamma} by Rosiglitazone Protects Human Islet Cells against Human Islet Amyloid Polypeptide Toxicity by a Phosphatidylinositol 3'-Kinase-Dependent Pathway J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6678 - 6686. [Abstract] [Full Text] [PDF]

				H. K.R. Karlsson, K. Hallsten, M. Bjornholm, H. Tsuchida, A. V. Chibalin, K. A. Virtanen, O. J. Heinonen, F. Lonnqvist, P. Nuutila, and J. R. Zierath Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study Diabetes, May 1, 2005; 54(5): 1459 - 1467. [Abstract] [Full Text] [PDF]

				M Schutt, J Zhou, M Meier, and H H Klein Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells J. Endocrinol., December 1, 2004; 183(3): 445 - 454. [Abstract] [Full Text] [PDF]

				A. R. Gosmanov, G. E. Umpierrez, A. H. Karabell, R. Cuervo, and D. B. Thomason Impaired expression and insulin-stimulated phosphorylation of Akt-2 in muscle of obese patients with atypical diabetes Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E8 - E15. [Abstract] [Full Text] [PDF]

				K. Levin, O. Hother-Nielsen, J. E. Henriksen, and H. Beck-Nielsen Effects of Troglitazone in Young First-Degree Relatives of Patients With Type 2 Diabetes Diabetes Care, January 1, 2004; 27(1): 148 - 154. [Abstract] [Full Text] [PDF]